Hepatitis C Virus

ICN Pharmaceuticals Pleads Guilty To Securities Fraud For Virazole

Published in Hepatitis Weekly, January 7th, 2002

ICN Pharmaceuticals, Inc., has agreed to plead guilty to one count of federal securities fraud and pay a $5.6 million fine for failing to disclose that its drug ribavirin would not be approved as a sole treatment for hepatitis C.

The Costa Mesa, California-based company, which was arraigned December 17, 2001, in U.S. District Court, also will be placed on three years probation and must create a corporate compliance program to prevent future violations, U.S. Attorney John S. Gordon said. The company also must pass annual certifications of compliance.

"ICN is pleased that this six-year-old investigation has been put behind us," the company said in a...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hepatitis Weekly

Source: Hepatitis Weekly (2002-01-07)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry